Wells Fargo & Company upgraded Definium Therapeutics, Inc. (NASDAQ: DFTX) to a strong-buy rating on Tuesday. The biotechnology firm develops therapeutics for psychiatric and neurological disorders.
Definium currently manages four Phase 3 trials for its lead candidate, DT120 ODT. The FDA granted this candidate Breakthrough Therapy Designation for Generalized Anxiety Disorder (GAD).
The company recently reported a quarterly loss of ($0.71) per share. This financial result fell below analyst consensus estimates.